



August 8, 2017

Tandem Diabetes Care Announces Issuance of Patent Related to Important Safety Features for Portable Infusion Pumps that Utilize Touchscreen Control

SAN DIEGO--(BUSINESS WIRE)-- Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, today announced the issuance of U.S. Patent No. 9,715,327 titled "*Preventing Inadvertent Changes in Ambulatory Medical Devices*". The patent relates to important safety features for the prevention of inadvertent changes in touchscreen enabled ambulatory infusion pumps, including insulin pumps. The touchscreen may be on the pump itself or be in wireless communication with a pump.

"We are the first and only company to receive FDA approval of an insulin pump with a touchscreen. This patent significantly strengthens our intellectual property position surrounding Tandem's user interface and the implementation of important features in other ambulatory infusion pumps that utilize touchscreen control," said Kim Blickenstaff, President and Chief Executive Officer of Tandem Diabetes Care. "This new patent validates the novel solutions we developed to give users the security of operating a life-sustaining medical device using a touchscreen and protects the creative solutions developed at Tandem."

The user interface for the t:slim, t:slim X2, t:flex and t:slim G4 Insulin Pumps were developed based on information and feedback collected from thousands of interviews, focus groups and online surveys to understand what people with diabetes, their caregivers and healthcare providers wanted in order to improve diabetes therapy management. The Company also utilized human factors research in its development process so that users can more successfully operate their insulin pump in its intended environment.

U.S. Patent No. 9,715,327 is scheduled to expire in 2033. The Company has a related U.S. continuation application on file, as well as a pending application in Europe.

Tandem Diabetes Care now has 55 issued U.S. patents and 51 pending U.S. patent applications. In addition, the Company has, and is seeking, patent protection for proprietary technologies in other countries throughout the world.

About Tandem Diabetes Care, Inc.

Tandem Diabetes Care, Inc. (www.tandemdiabetes.com) is a medical device company with an innovative, user-centric and integrated approach to the design, development and commercialization of products for people with diabetes who use insulin. The Company manufactures and sells the t:slim X2™ Insulin Pump, the slimmest and smallest durable insulin pump currently on the market, the t:flex® Insulin Pump, the first pump designed for people with greater insulin requirements, and the t:slim G4™ Insulin Pump, the first continuous glucose monitoring-enabled pump with touch-screen simplicity. Tandem is based in San Diego, California.

Follow Tandem Diabetes Care on Twitter @tandemdiabetes; use #tslimX2, #tslimG4, #tflex, #tconnect, and \$TNDM.

Follow Tandem Diabetes Care on Facebook at www.facebook.com/TandemDiabetes.

Follow Tandem Diabetes Care on LinkedIn at <https://www.linkedin.com/company/tandemdiabetes>.

Tandem Diabetes Care, t:connect and t:flex are registered trademarks, and t:slim X2 and t:slim G4 are trademarks of Tandem Diabetes Care, Inc. All other trademarks are the property of their respective owners.

Forward Looking Statement

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. These forward-looking statements relate to, among other things the scope and enforceability of the company's intellectual property, including the expected expiration of the 9,715,327 patent. Many factors could cause the company's actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements, including without limitation, those listed under the heading "Risk Factors" in the company's most recent Annual Report on Form 10-K, Quarterly Report on Form 10-Q and other documents that Tandem files with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Tandem undertakes

no obligation to update or review any forward-looking statement in this press release because of new information, future events or other factors.

View source version on [businesswire.com](http://www.businesswire.com/news/home/20170808005337/en/): <http://www.businesswire.com/news/home/20170808005337/en/>

Tandem Diabetes Care, Inc.

Media Contact:

Steve Sabicer, 714-907-6264

ssabicer@thesabicergroup.com

or

Investor Contact:

Susan Morrison, 858-366-6900 x7005

smorrison@tandemdiabetes.com

Source: Tandem Diabetes Care, Inc.

News Provided by Acquire Media